Table 1.
Characteristics of CML-CP patients in this study
| Factors | N=79 |
|---|---|
| Age, N | 44 (range 13-76) |
| Sex, male, N (%) | 48 (60.8%) |
| Sokal risk, N (%) | |
| Low-risk | 39(49.4%) |
| Intermediate-risk | 23(29.1%) |
| High-risk | 17(21.5%) |
| Hasford risk, N (%) | |
| Low-risk | 49(62.0%) |
| Intermediate-risk | 26(32.9%) |
| High-risk | 4(5.1%) |
| Interval since diagnosis, weeks, median (range) | 2(1-40) |
| Daily doses of imatinib (mg/day), median (range) | 400(300-600) |
| Baseline BCR-ABL1IS (%), median (range) | 65.1 (1.8-667.2) |
| Prior treatment | |
| None (%) | 49(62.0%) |